Returns Based on a $100,000 Investment
|
|
- Magnus Holt
- 6 years ago
- Views:
Transcription
1 A Leading Developer of Stem Cell Treatment Centers Fact Sheet 2016 Bioscience Americas, LLC Fund Data: Series 1: $15,000,000 Minimum Investment: $25,000 Type: Holdings: ) Investor Benefits: Private placement State-of-the-art stem cell treatment centers in the U.S. and Latin America 31% average annualized returns* Consistent cash flow paid quarterly Cash payout upon sale of centers to institutional investor or IPO projected to generate up to 10X ROI within 4 to 5 years Early cash-out option in 24 months, investors may elect cash-out and to receive their principal, plus pro-rata share of profits to date, paid-in-full Tax deferral through investment in self-directed IRA and 401(k) plans Compatible with 1031 exchange transactions (restrictions apply) As a recognized leader in developing, marketing, and managing stem cell treatment centers, Bioscience Americas is already taking advantage of the latest ground-breaking advancements in stem cell therapies to: Treat sports-related and orthopedic injuries, such as to knees and hips. These are the same treatments featured in the media that professional athletes are receiving to heal more quickly from injuries and surgeries. Treat life-threatening and debilitating diseases including Alzheimer s disease, Parkinson s disease, leukemia, and many other conditions. These advanced therapies can even help regenerate spinal cord cells to help paralyzed patients improve their quality of life. With a booming market for healthcare worldwide, soaring demand for medical care, and a rapidly aging population, Bioscience Americas is developing a global network of stem cell treatment centers to generate high income creating a pre-ipo opportunity to offer exceptional returns. About Proven track record 4,000 patients successfully treated since 2011 Awarded more than $400 million in research grants from government agencies such as NIH, and private organizations including the Christopher Reeve Foundation Established associations with leading research centers including UCLA, Harvard Medical School, the Salk Institute for Biological Studies, and many others International partnership the Global Institute of Stem Cell Therapy and Research (GIOSTAR), known as the global leaders in Stem Cell Technology 9 clinics already in development or under management Investment Strategy Develop state-of-the-art stem cell therapy centers in strategic locations in the U.S. and Latin America Meet the growing demand for treatment in underserved markets to generate high income, with quarterly distributions to investors Exit strategy, resell high-performing treatment centers at a significant profit to institutional investors or take the company public through an IPO Returns Based on a $100,000 Investment Avg. Years 2016 *Projections 2017 based 2018 on current target prospects Total Annual Exit 4 to 5 years THESE PROJECTIONS ARE PRESENTED FOR ILLUSTRATIVE Returns PURPOSES ONLY AND DO NOT Cash REPRESENT -- $4k A GUARANTEE $16k $48k Flow OF $87k FUTURE $155k RETURNS. 31% Projecting 4X to 10X ROI Through sale of company or assets to large ROI % -- 4% 16% 48% 87% 155% company, institutional investor or IPO THESE PROJECTIONS ARE PRESENTED FOR ILLUSTRATIVE PURPOSES ONLY AND DO NOT REPRESENT A GUA RANTEE OF FUTURE RETURNS. THIS IS NOT AN OFFER TO SELL A SECURITY OR A GENERAL SOLICITATION. AN OFFER TO SELL A SECURITY ONLY MAY BE MADE BY A PRIVATE PLACEMENT MEMORANDUM TO PRE-EXISTING SOPHISTICATED AND/OR ACCREDITED INVESTORS WHERE PERMITTED BY LAW. THIS CONTENT IS PROVIDED FOR GENERAL INFORMATIONAL PURPOSES ONLY. NOTHING HEREIN SHALL BE CONSTRUED AS TAX, LEGAL, INVESTMENT OR ACCOUNTING ADVICE. THERE ARE NO GUARANTEES THAT ANY RETURNS WILL BE ACHIEVED. POTENTIAL INVESTORS SHOULD CONSULT THEIR ATTORNEY, ACCOUNTANT, AND FINANCIAL ADVISORS BEFORE INVESTING.
2 A Leading Developer of Stem Cell Treatment Centers Table As on seen back on: that 100+ Years Combined Experience 9 Clinics In Development & Under Management Proven Track Record Management Team Eric Stoffers, CEO With more than fifteen years of business and executive experience, Mr. Stoffers has taken on key leadership roles in many business ventures with experience managing commercial properties including a medical resort facilities in Mexico and a major U.S. restaurant chain. His expertise incudes sales, outsourcing, recapitalization, acquisition, dispositions, and development. He holds a degree in Business Administration and from Northern Arizona University. Dr. Anand Srivastava, PhD Dr. Srivastava enjoys a worldwide reputation as one of the leading experts in stem cell biology, gene therapy, and clinical research. His work has been published in scientific journals cited extensively by other scientists and has been recognized by his peers through highly prestigious awards, plus invitations to present his work at international scientific conferences. He now leads scientific research at various institutions including UCLA and the Salk Research Institute, among others. A Ground-Floor Opportunity: The Rapidly Surging Demand for Stem Cell Therapy Offers Exceptional Investment Potential Here s why: As the world population continues to age, the number of people over the age of 60 will reach 1 billion by 2020 doubling in only the last 25 years Global spending for healthcare, a sector little impacted by economic recessions, will reach $12 trillion by New stem cell treatments for many diseases are not available in the U.S., but many insurance companies will pay for these treatments The U.S. medical tourism market, already $55 billion per year, continues to grow. Stem cell therapies for orthopedic & sports related treatments will reach $42 billion by 2018 and $51 billion by Opening 4 new strategically located clinics in 2017 Meeting the needs of an enormous underserved market Testimonials This is the group to invest with. The Bioscience Americas Team has delivered well beyond our expectations. John & Nancy M., Investors I cannot speak highly enough about Eric and his team. I used my self-directed IRA to invest and they were there to walk me through the entire process. David C., Physician I ve worked with Eric and his team for years. They re always a step ahead of the curve. Jeffrey J., Real Estate Broker For more information: Call: info@bioscienceamericas.com This is a rare opportunity to invest with us as we build new stem cell treatment centers, develop them to generate high income, and then sell them at a substantial profit to larger institution or go public via an IPO. Eric Stoffers, CEO, Bioscience Americas
3 SOLUTIONS FOR A HEALTHIER WORLD THROUGH ADVANCED STEM CELL THERAPIES PROSPECTUS $15,000,000 (1,500 Units at $10,000 per Unit) Minimum Subscription $25,000 A PRIVATE OFFERING TO ACCREDITED INVESTORS ONLY THIS MEMORANDUM IS FOR OVERALL INFORMATION PURPOSES ONLY. THIS IS NOT AN OFFER TO SELL A SECURITY OR A GENERAL SOLICITATION. AN OFFER TO SELL A SECURITY MAY BE MADE ONLY BY A PRIVATE PLACEMENT MEMORANDUM TO PRE-EXISTING SOPHISTICATED AND/OR ACCREDITED INVESTORS WHERE PERMITTED BY LAW. PERSONS INTERESTED IN INVESTING AND WHO ARE QUALIFIED TO INVEST, SHOULD CONTACT THE COMPANY AT TO OBTAIN FURTHER INFORMATION.
4 Bioscience Americas, a leading developer of stem cell treatment centers, was founded to bring adult stem cell-based regeneration and rejuvenation treatment to patients worldwide. The company is the international development partner of the Global Institute of Stem Cell Therapy and Research (GIOSTAR), recognized as the world s leading stem cell research consortium, dedicated to creating cures for life-threatening autoimmune diseases and healing injuries through the latest innovations in stem cell therapies. With a proven-track-record and more than 100 years of combined experience, Bioscience Americas leadership has been featured on CNBC, Fox News, Bloomberg, and The Wall Street Journal. Since 2011, more than 4,000 patients have successfully treated at the company s research facility at the UC San Diego Medical Center and flagship hospital in India. Now partnering with investors to expand its market in the U.S., Canada and Latin America, Bioscience America s investment strategy is to build, develop, and market high-income producing stem cell therapy clinics in these markets then resell these high income generating clinics to a larger organization or through an IPO. This strategy offers investors a low-risk, high-potential-reward opportunity.
5 Executive Team Eric Stoffers, CEO Mr. Stoffers is an internationally recognized author, investment manager, and philanthropist. With more than fifteen years of business and executive experience, Mr. Stoffers has taken on key leadership roles in many business ventures managing commercial properties including medical resort facilities in Mexico and a major U.S. restaurant chain. Eric s track record demonstrates proven success at scaling businesses and increasing investor and shareholder value. His expertise includes mergers & acquisitions, recapitalization, and development. He holds a degree in Business Administration from Northern Arizona University. Dr. Anand Srivastava, Ph.D. Chief Scientific Officer, GIOSTAR Dr. Srivastava is a world-renowned expert in stem cell biology, gene therapy, and clinical research. His work has been published in widely respected scientific journals cited extensively by other scientists and has been recognized by his peers through highly prestigious awards, plus invitations to present his work at international scientific conferences. He now leads scientific research at various institutions including University of California San Diego, UCLA, and the Salk Research Institute, among others. Dr. Leslie Miller Dr. Miller is an internationally renowned cardiologist and expert in the field of heart failure and transplantation. He has served as an investigator in over one hundred clinical trials and has refocused his research on the use of stem cells to treat heart disease. Dr. Miller previously served as the Director of the cardiac programs at Georgetown University School of Medicine, Washington Hospital Center as well as the University of Minnesota. He has received numerous awards from both fellows and residents, including teacher of the year in internal medicine and the Proctor Harvey Chair.
6 Investment Overview Bioscience Americas, LLC Purpose of Fund: Offer accredited investors low-risk, high potential reward investment opportunities to capitalize on the emerging stem cell therapy market Manager Bioscience Capital, LLC Initial Offering $15,000,000 Number of Units / Price per Unit 1,500 ($10,000 per Unit) Minimum Subscription $25,000 Use of Proceeds Build and develop state-of-the-art stem cell therapy clinics in the U.S., Canada, and Latin America Projected Returns 31% average annualized returns over 5 years Fund Objectives Build, develop, and market high-income producing stem cell therapy clinics in strategic locations in partnership with leading global stem cell research institute GIOSTAR. Distribute cash flow as quarterly payments to investors with expected 31% average annualized returns over 5 years. Exit strategy: Resell high-income producing clinics to a large organization or issue public IPO with a projected ROI of up to 10X within 4 to 5 years. 24-Month Cash Out Option Investors may choose to exercise an option to cash out after 24 months and receive principal plus pro-rata share of profits to date, paid-in-full.
7 Executive Summary Bioscience Americas was founded to capitalize on the emerging demand for stem cell therapy by building and developing high-income producing treatment clinics, then sell these clinics for a significant profit. Our investment strategy: o Develop high income producing state-of-the-art stem cell therapy clinics in strategic locations with our development partner GIOSTAR, known worldwide as leaders in stem cell treatment technologies o Provide cash flow to investors through quarterly distributions o Resell high-performing and high-producing clinics to a larger organizations or take company public by issuing IPO Bioscience Americas and its partners have invested their own time and money for research, detailed studies, and due diligence for each clinic to identify optimum opportunities that minimize risk and offer the potential for significant returns. Investment Allocation An excellent fit for the medium- to low-risk allocation of your investment portfolio
8 A Proven Track Record More than 100 years of combined experience. 9 clinics in development, and under management. Proven expertise in developing and operating profitable stem cell therapy clinics. Since 2011, successfully treated more than 4,000 patients. Development partner GIOSTAR recognized as one of the world s leading stem cell research institutions with 15 years of experience and scientists associated at institutions including: UC San Diego UCLA UC Irvine Vanderbilt University Harvard University Salk Institute University of California Medical Center Awarded more than $400 million in research grants, endowment contributions, and legislative appropriations. Investor Benefits: Average annual return of 31% Quarterly cash flow distributions Option to cash out in 24 months Exit strategy of reselling high-income producing clinics to large company or issue an IPO This is a rare opportunity to invest with us as we build new stem cell treatment centers, develop them to generate high income, and then sell them at a substantial profit to larger institutions or go public via an IPO. - Eric Stoffers, CEO, Bioscience Americas
9 Projected Returns on Investment Summary Summary o 31% average annualized returns o 87% distribution in year 5 o Up to 10X ROI by year 5 based on exit strategy to resell to large company, institutional investor or via IPO o Cash out option: Investors may cash out in 24 months and receive their principal plus pro-rata share of profits, paid-in-full THESE PROJECTIONS ARE PRESENTED FOR ILLUSTRATIVE PURPOSES ONLY AND DO NOT REPRESENT A GUARANTEE OF FUTURE RETURNS. This is not an offer to sell a security or a general solicitation. An offer to sell a security can only be made by a private placement memorandum to preexisting sophisticated and/or accredited investors where permitted by law. This content is provided for general informational purposes only. Nothing herein shall be construed as tax, legal, investment or accounting advice. There are no guarantees that any returns wi ll be achieved. Potential investors should consult their attorney, accountant, and financial advisors before investing.
10 Frequently Asked Questions Does Bioscience Americas use embryonic stem cells? Bioscience Americas does not use embryonic stem cells in our treatments or therapies. We use a patient s own autologous, or adult, stem cells that we source from the patient s fatty tissue or bone marrow. Our scientists take the patient s stem cells, multiply them by the millions, and through a process called induced pluripotent convert them to the embryonic stage and direct the cells to where in the body they want them to go. What is Bioscience Americas track record? With 100+ years of combined experience, Bioscience Americas executives have earned millions of dollars in investor returns over the past 20 years. Since 2011, Bioscience Americas and research partner GIOSTAR have treated 4,000 patients through the latest innovations in stem cell therapies to cure life-threatening diseases and heal debilitating injuries and has been awarded more than $400 million in research grants, endowment contributions, and legislative appropriations. How do I get started? Call our Investor Relations Department at or info@bioscienceamericas.com. We ll answer your questions and discuss your financial goals to determine if this is an appropriate investment to meet those goals. If you prefer to meet in person, we ll be happy to schedule a meeting with you in our Phoenix or New York office. What type of return can I expect on my investment? We project an average annual return on investment of 31% over the first 5 years. When do I start receiving quarterly dividend checks? Quarterly dividend payments are projected to begin in How long before my principal is paid back in full? Based on our projections we estimate that by year 4 or 5, quarterly dividends will represent full return of principal plus a substantial ROI. Contact us for further details. Can I cash out early? Yes, investors have the option to cash out in 24 months to receive return of principal plus their pro-rate share of profits to date.
11 Frequently Asked Questions Continued What is Bioscience America s Exit Strategy? After building and developing high-income-producing stem cell therapy clinics, these clinics will be sold to a larger company or by issuing a public IPO. Why invest with Bioscience Americas? Exceptional returns through consistent quarterly dividends Proven track record in developing profitable clinics and successfully treating patients Experienced leadership well positioned to take advantage of a growing market, minimize risk, and earn significant returns Excellent growth potential with up to 10X ROI projected upon sale to a larger company or initial public offering Leveraging the latest technology already funded in part through $400 million awarded through research grants by government and private organizations Recession-resistant healthcare industry sector What Our Investors Say This is the group to invest with. The Bioscience Americas Team has delivered well beyond our expectations. -- John and Nancy M. - Investors I cannot speak highly enough about Eric and his team. I used my self-directed IRA to invest and they were there to walk me through the entire process. -- David C., MD I ve worked with Eric and his team for years. They re always a step ahead of the curve. Now partnering with GIOSTAR, I m confident they will help positively impact thousands of people s lives with their ground-breaking medical breakthroughs and I m honored to be a part of it. -- Jeffrey J. Real estate broker
12 Invest with Bioscience Americas Expertise, experience and proven-track-record to help investors capitalize on high-potential-reward opportunities in a rapidly expanding healthcare market. Call our Investor Relations department today! info@bioscienceamericas.com 2122 E Highland Avenue, Suite 265 Phoenix, AZ
Cardio3 BioSciences Raises EUR 23.0 million in Successful Initial Public Offering on NYSE Euronext Brussels and NYSE Euronext Paris
This announcement is not an offer to sell, or a solicitation of an offer to acquire any securities. This announcement is an advertisement and not a prospectus and investors should not purchase any securities
More informationNOVOHEART HOLDINGS INC. Suite West Pender Street Vancouver British Columbia V6C 2V6 Canada
October 25, 2017 NOVOHEART HOLDINGS INC. Suite 1430 800 West Pender Street Vancouver British Columbia V6C 2V6 Canada Novoheart Holdings Inc. Reports Fourth Quarter and Fiscal 2017 Financial Results Vancouver,
More informationWhat You should Know about Medical Travel and the Potential Impact on the Cost of Your Healthcare Benefits!
What You should Know about Medical Travel and the Potential Impact on the Cost of Your Healthcare Benefits! PRESENTED BY Terry W. White March 12, 2009 Presentation Overview Problem: US Healthcare system
More informationdj Orthopedics Announces Financial Results for Second Quarter 2004 and Integration Plans for Regentek Business Segment
dj Orthopedics Announces Financial Results for Second Quarter 2004 and Integration Plans for Regentek Business Segment SAN DIEGO, July 27 /PRNewswire-FirstCall/ -- dj Orthopedics, Inc., (NYSE: DJO), a
More information2012 SUMMARY REPORT PG 1
2012 SUMMARY REPORT PG 1 100 MILLION PEOPLE City of Hope scientists helped create medicines that benefit 100 million people worldwide each year. 15 FIRST-IN-HUMAN CLINICAL TRIALS City of Hope has created
More informationHealth Services in Jordan and Quality of Care
Health Services in Jordan and Quality of Care Private Hospitals Association Dr. Abdalla Bashir Amman, June 2010 Jordan Jordan is undergoing a transformation into an international business hub centering
More informationDJO Global, Inc. Company Presentation. June 2013
DJO Global, Inc. Company Presentation June 2013 Safe Harbor Statement This presentation has been prepared by DJOFL. The information contained in this presentation is for information purposes only. The
More informationManagement Discussion and Analysis
Management Discussion and Analysis For the Year Ended December 31, 2016 Henry Ford Health System and its affiliates (the System) Management s Discussion and Analysis (MD&A) is intended to provide a high
More informationInternational Stem Cell
International Stem Cell Third cohort ready to go Financial update Pharma & biotech International Stem Cell (ISCO) recently announced that the data safety monitoring board for its Phase I trial of ISC-hpNSC
More informationDrug Royalty II $701,420,000. Presentation to: San Diego County Employees Retirement Association
Drug Royalty II $701,420,000 Presentation to: San Diego County Employees Retirement Association November 2010 Profile Business Model Team Investment Criteria To acquire Royalty Streams on established commercialized
More informationINSURANCE FOR THE HEALTHCARE INDUSTRY
INSURANCE FOR THE HEALTHCARE INDUSTRY YOUR WORLD, OUR KNOWLEDGE In your world, the patient comes first. Every minute of every day, you are focused on them. In our world, you come first. For more than half
More informationACTION ITEM EXECUTIVE SUMMARY
Office of the President TO MEMBERS OF THE COMMITTEE ON HEALTH SERVICES: For Meeting of ACTION ITEM APPROVAL OF APPOINTMENT OF AND COMPENSATION USING NON-STATE FUNDS FOR PAUL A. STATON AS SENIOR VICE PRESIDENT
More informationFortress Biotech Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
Fortress Biotech Reports First Quarter 2018 Financial Results and Recent Corporate Highlights New York, NY May 10, 2018 Fortress Biotech, Inc. (NASDAQ: FBIO) ( Fortress ), a biopharmaceutical company dedicated
More informationTailored solutions for Merger & Acquisition risks. Equity and M&A
Tailored solutions for Merger & Acquisition risks. Equity and M&A The Gallagher difference. The Gallagher Equity and M&A team has experience that covers the entire mergers and acquisitions spectrum, including
More informationEXPERTISE AND GUIDANCE TO SMALL-CAP COMPANIES INVESTOR RELATIONS PHOENIX NEW YORK
EXPERTISE AND GUIDANCE TO SMALL-CAP COMPANIES INVESTOR RELATIONS PHOENIX NEW YORK INVESTOR RELATIONS INVESTOR RELATIONS SOLUTIONS FOR THE WORLD S INNOVATIONS SINCE 1994 Lytham Partners is one of the country's
More informationFOR IMMEDIATE RELEASE
Company Investor/Media Contact: DJO Incorporated Mark Francois, Director of Investor Relations (760) 734-4766 mark.francois@djoglobal.com FOR IMMEDIATE RELEASE DJO INCORPORATED ANNOUNCES FINANCIAL RESULTS
More informationGALLAGHER EQUITY ADVISORS PRACTICE
GALLAGHER EQUITY ADVISORS PRACTICE The Gallagher Difference The Gallagher Equity Advisors team has experience that covers the entire mergers and acquisitions spectrum, including private equity, venture
More informationdj Orthopedics Announces Record Net Revenues and Earnings For Third Quarter 2003
dj Orthopedics Announces Record Net Revenues and Earnings For Third Quarter 2003 SAN DIEGO, Oct 28, 2003 /PRNewswire-FirstCall via COMTEX/ -- dj Orthopedics, Inc. (NYSE: DJO), a designer, manufacturer
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationAVITA Medical Fourth Quarter 2018 Quarterly Cash Flow Report and Company Update
ASX/News Release AVITA Medical Fourth Quarter 2018 Quarterly Cash Flow Report and Company Update Recent Highlights Published pivotal clinical trial results in second-degree burns in Journal of Burn Care
More information$20 MILLION PREFERRED EQUITY OFFERING
$20 MILLION PREFERRED EQUITY OFFERING This is neither an offer to sell nor a solicitation of an offer to buy interests in L Auberge de Sonoma Resort Fund, LLC (the Fund ). An offering is made only by the
More informationInotek Pharmaceuticals Announces Merger Agreement with Rocket Pharmaceuticals to Advance Pipeline of First-in-Class Gene Therapies for Rare Diseases
Inotek Pharmaceuticals Announces Merger Agreement with Rocket Pharmaceuticals to Advance Pipeline of First-in-Class Gene Therapies for Rare Diseases - Company to Leverage Lentiviral and AAV Gene Therapy
More informationMYnd Analytics and Emmaus Life Sciences Provide Update to Shareholders Addressing Questions Related to Merger and Spin-off Transaction
Filed by MYnd Analytics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14-a-12 of the Securities Exchange Act of 1934 Subject Corporation: MYnd Analytics,
More information32110 Agoura Road Westlake Village, CA Ph Fax Contact for more information: Ken Doyle.
32110 Agoura Road Westlake Village, CA 91361-4026 Ph. 800-801-2300 Fax 800-609-0111 Contact for more information: Ken Doyle media kit Who is Warner Pacific? Founded in 1982, Warner Pacific serves more
More informationCompany Overview. Financial Performance
Jan/15 Feb/15 Mar/15 Apr/15 May/15 Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/15 Dec/15 KMC Speciality Hospitals India Ltd CMP: 7.61 January 21, 2015 Stock Details BSE code 524520 BSE ID KMCSHIL Face value
More informationdj Orthopedics Announces Second Quarter Results; Net Revenues Grow 8.9% to $68.8 Million; Earnings Per Share Grow to 31 Cents
dj Orthopedics Announces Second Quarter Results; Net Revenues Grow 8.9% to $68.8 Million; Earnings Per Share Grow to 31 Cents dj Orthopedics Announces Second Quarter Results; Net Revenues Grow 8.9% to
More informationCannabics Pharmaceuticals, Inc. Breakthrough Cannabis Medications - Review and Outlook.
Cannabics Pharmaceuticals, Inc. Breakthrough Cannabis Medications - Review and Outlook. Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX), is engaged in the development of Personalized Anti- Cancer treatments.
More informationJune Dear Fellow Takeda Shareholder,
June 2018 Dear Fellow Takeda Shareholder, Since joining Takeda in April 2014, my mission has been to continue the transformation of Takeda in order to ensure that Takeda will be a successful company in
More informationSan Francisco Health Service System
San Francisco Health Service System Innovation Day Attendees and Subject Matter Expert Biographies June 22, 2018 SFHSS Innovation Day Attendees Health Service Board Attendees Health Service System Attendees
More informationHENRY M. SEYBOLD, JR., CPA, MBA 529 S. Summit Street (C)
HENRY M. SEYBOLD, JR., CPA, MBA 529 S. Summit Street (C) 815-997-3278 Barrington, IL 60010 hseybold@yahoo.com Mr. Gary Hamm President Healthcare Placement Group 30021 Tomas Suite 210 Rancho Santa Margarita,
More information2017 Third Quarter Trading Report Supporting healthcare professionals for over 150 years
2017 Third Quarter Trading Report Supporting healthcare professionals for over 150 years 1 Forward looking statements This document may contain forward-looking statements that may or may not prove accurate.
More informationBY ELECTRONIC MAIL TO
BY ELECTRONIC MAIL TO NONPROFITIPREGS@CIRM.CA.GOV Mr. C. Scott Tocher Interim Counsel California Institute for Regenerative Medicine 250 King Street San Francisco, CA 94107 Comments to Proposed Changes
More informationOhr Pharmaceutical Reports Financial Results for the Fiscal First Quarter of 2019
February 14, 2019 Ohr Pharmaceutical Reports Financial Results for the Fiscal First Quarter of 2019 Stockholder vote on the proposed merger with NeuBase Therapeutics anticipated in the second calendar
More informationTo Acquire. Creating the first and only global, comprehensive virtual healthcare delivery platform. June 19, 2017
To Acquire Creating the first and only global, comprehensive virtual healthcare delivery platform June 19, 2017 1 Today s Presenters Jason Gorevic President & CEO Mark Hirschhorn COO & CFO Peter McClennen
More informationMicroPort Scientific Corporation Announces HKEx Main Board Listing Details
MicroPort Scientific Corporation Announces HKEx Main Board Listing Details ******************************************************** Global Offering of 252,740,000 Shares At between HK$4.60 and HK$6.10
More informationPediatric Brain Tumor Foundation of the United States, Inc.
Pediatric Brain Tumor Foundation of the United States, Inc. Financial Statements Years Ended December 31, 2016 and 2015 Pediatric Brain Tumor Foundation 0f The United States, Inc. Table of Contents Independent
More informationOrthofix International N.V.
Orthofix International N.V. NASDAQ:OFIX Brad Mason - President & CEO Safe Harbor Statement Except for historical information contained herein, the statements made in this presentation constitute forward
More informationLaunching a HEDGE FUND in 2017: KEY STRUCTURAL AND OPERATIONAL ISSUES
Launching a HEDGE FUND in 2017: KEY STRUCTURAL AND OPERATIONAL ISSUES FUND FORMATION SERVICES What sort of legal structure should be used? Most domestic hedge funds are organized as limited partnerships
More informationLet s Plan Your Future Together
Let s Plan Your Future Together Comprehensive Financial Planning insight2wealth.com (800) 878-1665 Life Happens We Listen ABOUT INSIGHT WEALTH STRATEGIES Insight Wealth Strategies is a comprehensive financial
More informationGenSight Biologics launches its Initial Public Offering on the regulated market of Euronext in Paris
Press Release GenSight Biologics launches its Initial Public Offering on the regulated market of Euronext in Paris Capital increase of approximately 40 million, which may be increased to a maximum of approximately
More informationMRI INTERVENTIONS, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationCytori Reports First Quarter 2014 Business and Financial Results
CYTORI THERAPEUTICS CONTACT Megan McCormick +1.858.875.5279 mmccormick@cytori.com Cytori Reports First Quarter 2014 Business and Financial Results San Diego, CA, May 12, 2014 Cytori Therapeutics (NASDAQ:
More informationWHY? Abbot Downing Advisor Joins PagnatoKarp WHY HAVE I JOINED PAGNATOKARP?
WHY? Abbot Downing Advisor Joins PagnatoKarp WHY HAVE I JOINED PAGNATOKARP? The financial services landscape has caused me to question the large integrated firm model. My inherent fiduciary responsibility
More informationManaging the risk and unpredictable costs of transplants
Managing the risk and unpredictable costs of transplants Executive summary While payers understand that transplants will be a part of their medical expense, they may be unprepared for the financial volatility
More informationCell Therapies and Bioengineering Conference Sponsorship Opportunities
Cell Therapies and Bioengineering Conference Sponsorship Opportunities September 20-22, 2018 San Francisco, California Presented by the Society of Biological Engineering (SBE), the first Conference on
More informationWELCOME TO THE NEXT CHAPTER
Insured and locally Internationally WELCOME TO THE NEXT CHAPTER A GUIDE TO OUR NEW RANGE OF GLOBAL HEALTH PLANS October 2015 WELCOME TO THE NEXT CHAPTER OF GLOBAL HEALTHCARE We have never wanted to be
More informationArix Bioscience plc Half-Yearly Report and Consolidated Interim Financial Statements Six months ended 30 June 2017
Arix Bioscience plc Half-Yearly Report and Consolidated Interim Financial Statements Six months ended 30 June 2017 CEO s Statement A vote of confidence in the life science sector In February 2017, Arix
More informationFortress Biotech Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
Fortress Biotech Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights New York, NY November 9, 2018 Fortress Biotech, Inc. (NASDAQ: FBIO) ( Fortress ), a biopharmaceutical company
More informationBiom Up announces the filing of its Document de base. within the framework of its planned IPO on the Euronext Paris regulated market.
Press release Biom Up announces the filing of its Document de base within the framework of its planned IPO on the Euronext Paris regulated market Saint-Priest, France, September 12, 2017 Biom Up, specialist
More informationCYTRX CORPORATION (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Earliest Event Reported)
More informationA flexible benefit plan that offers exclusive advantages to your key executives.
A flexible benefit plan that offers exclusive advantages to your key executives. ternian If you want to provide the very best for your organization s leaders, while complying with the complex regulations
More informationCuretis Announces Intention to Launch Its Initial Public Offering and Listing on Euronext Amsterdam and Euronext Brussels
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT
More informationPediatric Brain Tumor Foundation of the United States, Inc.
Pediatric Brain Tumor Foundation of the United States, Inc. Financial Statements Years Ended December 31, 2017 and 2016 Pediatric Brain Tumor Foundation 0f The United States, Inc. Table of Contents Independent
More informationAvita Medical Second Quarter Fiscal 2019 Quarterly Cash Flow Report and Company Update
ASX/News Release Avita Medical Second Quarter Fiscal 2019 Quarterly Cash Flow Report and Company Update Recent Highlights Pre-launch U.S. product sales of A$1.1 million in second quarter Successful preparation
More informationAn ACO Success Story: The Path to Market Leadership
An ACO Success Story: The Path to Market Leadership the decisions made in the primary care setting have important implications for downstream medical care...primary care physicians can be seen as a chief
More informationZimmer Biomet Reports Second Quarter 2016 Financial Results
July 28, 2016 Zimmer Biomet Reports Second Quarter 2016 Financial Results -- Net Sales of $1.934 billion represent an increase of 65.6% over the prior year period, and an increase of 4.5% on an adjusted
More informationThe IU Finance Department
The IU Finance Department Prof. Sreenivas Kamma, Chairperson December 2011 Always exciting High frequency trading - Flash crash Groupon IPO HP spin-off? Kraft Cadbury merger Always exciting High frequency
More informationCompetition is Healthy
Competition is Healthy How Medical Tourism is making changes in the US Healthcare System Presented By Rudy Rupak Who Are Medical Tourists? THE CONSUMER IS EVOLVING RAPIDLY Used to be the uninsured. Too
More informationADVERUM BIOTECHNOLOGIES, INC. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event
More informationINSTITUTE OF MEDICINE COMMITTEE ON THE DETERMINATION OF ESSENTIAL HEALTH BENEFITS
COMMENTS 1310 G Street, N.W. Washington, D.C. 20005 202.626.4780 Fax 202.626.4833 Before the INSTITUTE OF MEDICINE COMMITTEE ON THE DETERMINATION OF ESSENTIAL HEALTH BENEFITS On How Insurers Make Determinations
More informationCREATE THE OPPORTUNITY
CREATE THE OPPORTUNITY Actively Managed Private Equity Investments Since 1969 Established 1969 WE ARE THOROUGH, DILIGENT, AND RIGOROUS IN OUR APPROACH. AT THE SAME TIME WE ENCOURAGE MANAGEMENT TO BE INVENTIVE
More informationMergers & Acquisitions
Mergers & Acquisitions Mergers & Acquisitions Our Signature Story Since 1926, we have been a trusted business partner to our clients and have earned our reputation as one of the most respected and socially
More informationTargacept and Catalyst Biosciences Enter Definitive Merger Agreement Creating a Protease-Based Hemostasis and Anti-Complement Company
Targacept and Catalyst Biosciences Enter Definitive Merger Agreement Creating a Protease-Based Hemostasis and Anti-Complement Company Merger combines Catalyst s protease therapeutics pipeline and the financial
More informationThe Physician-Owned Management Services Organization
The Physician-Owned Management Services Organization By Joe Laden www.onemso.com/consulting A Management Services Organization (MSO) is a legal entity created to provide management and administrative services
More informationBUILDING SUCCESS. Company Overview
BUILDING SUCCESS. Company Overview www.venturerealestatecompany.com 513-407-9123 info@venturerealestatecompany.com Philosophy Vision, Mission, Values Building Success. At Venture, success is not simply
More informationCIGNA HealthCare of Southern California. Let Us Improve Your Health Healthier Employees, for a Healthier Business / a 09/07
CIGNA HealthCare of Southern California Let Us Improve Your Health Healthier Employees, for a Healthier Business 807596 03/07 807596a 09/07 Our Customer Commitments Improve health At CIGNA HealthCare of
More informationINTERNATIONAL BANKING
INTERNATIONAL BANKING WHAT OUR CLIENTS SAY We needed a likeminded partner as a banker that was committed to serving small and mid-sized companies, including those with international operations, by providing
More informationCritical HealthEvents. Insurance. Trustmark. When critical illness touches your life NAMED ONE OF THE MOST INNOVATIVE PRODUCTS OF 2015.
NAMED ONE OF THE MOST INNOVATIVE PRODUCTS OF 2015. Source: Lifehealthpro.com, May 15, 2015. http://www.lifehealthpro.com/2015/05/15/ the-6-most-innovative-industry-products-of-2015?page_all=1 Trustmark
More informationOber Kaler Health Law Client Alert
2014 Ober Kaler Health Law Client Alert CMS Self-Disclosure Protocol Overview, Practical Tips and Summary of Settlements Prepared by: Catherine A. Martin 1 Principal, Ober Kaler camartin@ober.com 410.347.7320
More informationInvestors are encouraged
Investors are encouraged to read the Prospectus for ATEL 17, LLC ( the Fund ) carefully. This brochure constitutes neither an offer to sell nor a solicitation of an offer to buy the securities described
More informationCraig D. Frances, M.D McGuire Woods Annual Conference October 10, 2009
The Financial World s View of ASCs Craig D. Frances, M.D. 2009 McGuire Woods Annual Conference October 10, 2009 Agenda What is private equity and its utility? Why consider a private equity partner? What
More informationSimplify, preserve and enhance.
Simplify, preserve and enhance. Your wealth is the cumulative result of your hard work, discipline, and astute management. Yet the opportunities it affords may also come with unique responsibilities,
More informationFortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights
Fortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights New York, NY November 9, 2016 Fortress Biotech, Inc. (NASDAQ: FBIO) ( Fortress ), a biopharmaceutical company
More informationSecuring Your Financial Future. There s Wealth in Our Approach.
The Right Game Plan Securing Your Financial Future There s Wealth in Our Approach. About Us Value Statement As a professional athlete, your earnings depend on many variables. You will most likely experience
More informationTailored Solutions for Merger & Acquisition Risks
Tailored Solutions for Merger & Acquisition Risks GALLAGHER EQUITY ADVISORS PRACTICE The Gallagher Difference The Gallagher Equity Advisors team has experience that covers the entire mergers and acquisitions
More informationHelp protect your future from one of life s uncertainties
Help protect your future from one of life s uncertainties GROUP LONG TERM CARE INSURANCE PROGRAM Underwritten by Genworth Life Insurance Company 46871 08/29/13 Revised 46871 07/02/15 Plan today In these
More informationCharbonneau Kennewick, WA. A Diversified Investment in Senior Housing
Charbonneau Kennewick, WA A Diversified Investment in Senior Housing Forward Looking Statements Investment Risks This sales material includes forward-looking statements that can be identified by the use
More informationSECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):
More informationShow your support for students and their families. Learn more about Zurich s Student Accident Coverage
Show your support for students and their families Learn more about Zurich s Student Accident Coverage At the high school basketball semi-finals, the unimaginable happened to 15-year-old guard Jack and
More informationInterview: Oak Street Funding s Rick Dennen
Interview: Oak Street Funding s Rick Dennen Rick Dennen is the founder, president and CEO of Oak Street Funding. Located in Indianapolis, Indiana, Oak Street is a family of diversified financial services
More informationdear fellow shareholders,
2013 annual report dear fellow shareholders, 2013 was a landmark year for Umpqua Holdings. We celebrated Umpqua Bank s 60th anniversary and the investments and actions taken over the last few years delivered
More informationTRANSACTION ADVISORY SERVICES. Customized, value-added solutions every step of the way
TRANSACTION ADVISORY SERVICES Customized, value-added solutions every step of the way TRANSACTION ADVISORY SERVICES 3 TABLE OF CONTENTS THE REHMANN EXPERIENCE TRANSACTION ADVISORY SERVICE OFFERINGS YOUR
More informationHalf Yearly Report Interim Results for the six months ended 30 September 2014
21 November 2014 Collagen Solutions Plc (the "Company" or the Group ) Half Yearly Report Interim Results for the six months ended 30 September 2014 Collagen Solutions plc (AIM: COS), the developer and
More informationZACKS INVESTMENT MANAGEMENT. Personalized Wealth Management INDEPENDENT. Research Thinking Results
Personalized Wealth Management INDEPENDENT Research Thinking Results HIGHLIGHTS: ZACKS INVESTMENT MANAGEMENT HAS A RESPECTED TRACK RECORD OF EXCEPTIONAL ASSET MANAGEMENT FOR OUR CLIENTS ZACKS INVESTMENT
More informationA leading provider of post acute services
A leading provider of post acute services November 2018 2018 by Genesis Healthcare, Inc. All Rights Reserved. Safe Harbor Statement Certain statements in this presentation regarding the expected benefits
More informationGLOBAL TRANSACTIONS FORECAST
2018 GLOBAL TRANSACTIONS FORECAST Healthcare A BAKER MCKENZIE SECTOR REPORT Deal activity to surge amid strong market conditions and US tax reform Uncertainty in the wake of Brexit, the US presidential
More informationCryoport Revenue Grows 59% for Second Quarter 2018; 73% in Biopharma IRVINE, California, August 9, 2018
Cryoport Revenue Grows 59% for Second Quarter 2018; 73% in Biopharma Revenue from Approved CAR-T Therapies Continues to Ramp; Record 258 Clinical Trials Now Supported by Cryoport, with 34 Programs in Phase
More informationLuther Burbank Corp (LBC) BUY
Luther Burbank Corp (LBC) BUY Upcoming IPO Priced Right for a Throwback Thrift December 2 nd, 2017 OVERVIEW We are initiating coverage on Luther Burbank Corporation with a BUY rating and $13.29 per share
More informationMEDICAL ARTS INSURANCE. a Horton Group Company. Specializing in Professional Liability, Employee Benefits and Insurance for Health Care Providers
MEDICAL ARTS INSURANCE a Horton Group Company Specializing in Professional Liability, Employee Benefits and Insurance for Health Care Providers MEDICAL ARTS INSURANCE PROVIDES BEST IN CLASS SOLUTIONS FOR
More informationSelling an Insurance Agency
Selling an Insurance Agency Financing for insurance professionals a complimentary whitepaper for agents and brokers How to get the right price from the right buyer As a wave of consolidation readies itself
More informationCreating an Oligopoly in the Treatment of End Stage Renal Disease and the Subsequent Impact on Home Hemodialysis Therapies in the United States
Creating an Oligopoly in the Treatment of End Stage Renal Disease and the Subsequent Impact on Home Hemodialysis Therapies in the United States John D Sullivan, Ph.D. Boston University Agenda History Disease
More informationFinancial Advisor Opportunities
Financial Advisor Opportunities 2018 B. Riley Wealth Management B. Riley Wealth Management (BRWM) is a boutique wealth management firm with a national presence Premier offices in major markets and regional
More informationMedical Travel for Self-Funded Employers
Medical Travel for Self-Funded Employers Orange County Employee Benefits Council Winter 2012 Presented By Jim DiFalco Medical Travel Consultant February 9, 2012 What Changed Since 2008? Facilitators focused
More informationCompany Overview. Financial Performance
Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 Nov-15 Dec-15 CMP: 31.25 December 24, 2015 Stock Details BSE code 523878 BSE ID TOTEX Face value ( ) 10 No of shares (m) 8.1 Market
More informationTake advantage. Diversify now.
Look into the future and health technology is the key to advancing our lives. We think its smart to diversify your investment dollars into the healthtech sector. We hope when you make this decision that
More informationBiotech Showcase 2019 Investment Trends Survey
Demy-Colton and EBD Group Biotech Showcase 2019 Investment Trends Survey December 7, 2018 Survey Overview Survey included 10 questions on biotech industry investment trends for 2019 Survey was sent to
More informationEnsure Network Adequacy. May 23, 2017
May 23, 2017 The Honorable Orrin Hatch Chairman, Senate Finance Committee 219 Dirksen Senate Office Building Washington, DC 20510 Sent electronically to HealthReform@finance.senate.gov Dear Mr. Chairman,
More informationSHORT WALKS. BIG BENEFITS.
SHORT WALKS. BIG BENEFITS. Optima Restore with Stay Active benefit. SAVE 2% SAVE 5% SAVE 8% Introducing Optima Restore Health Insurance Plan The Optima Restore isn`t just a regular health insurance plan.
More informationNew Approach to Retiree Health Care Coverage. New Choices Better Value
New Approach to Retiree Health Care Coverage New Choices Better Value What We ll Cover Today What s Changing and Why What You Need To Do Introducing Extend Health Understanding Supplemental Medicare Insurance
More informationCombination Creates Leading Innovator in the Musculoskeletal Industry April 24, 2014
Combination Creates Leading Innovator in the Musculoskeletal Industry April 24, 2014 David Dvorak President and Chief Executive Officer Jim Crines EVP, Finance, and Chief Financial Officer Cautionary Statement
More information